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Background: Expression and/or excretion of fibroblast growth factor-23 (FGF23) and its co-receptor Klotho are
altered in patients with end-stage renal disease. The possibility that the FGF23/α-Klotho system mediates the
aggravated cardiovascular outcome among patients with chronic kidney disease (CKD) has been suggested. We
determined whether FGF23 and α-Klotho concentrations are altered among patients with reduced renal function
and proteinuria.
Methods: Serum FGF23 and α-Klotho were measured in cardiology patients who were not undergoing chronic
hemodialysis. Estimated glomerular filtration rate (eGFR) was correlated negatively with FGF23 and positively with
α-Klotho.
Results: The correlation between FGF23 and the renal tubular maximum reabsorption rate of phosphate to the
GFR (TmP/GFR) was not significant, but that between FGF23 and serum calcium or inorganic phosphate was
significant among patients with an estimated GFR of less than 60 mL/min/m2. By stepwise multivariate regression
analysis, eGFR was selected as significant predictor for FGF23 or α-Klotho among patients with an estimated GFR of
less than 60 mL/min/m2; however, urine albumin/creatinine ratio was not selected as a predictor for FGF23 or
α-Klotho irrespective of the eGFR levels. In patients with eGFR of <60 mL/min/1.73 m2, UACR was significantly
associated with log(FGF23); but, this association did not remain statistically significant in a multivariate model.
Conclusions: Among cardiology patients with various stages of CKD, serum concentrations of FGF23 and α-Klotho
were associated with renal function, but not with the extent of proteinuria.
Keywords: Fibroblast growth factor-23, Klotho, Chronic kidney diseaseBackground
Fibroblast growth factor-23 (FGF23) plays a crucial role
in the regulation of calcium-phosphate metabolism by
suppressing the renal tubular reabsorption of phosphate
via activation of FGFR-1c in the presence of its co-
receptor Klotho, which was originally identified as an
anti-aging molecule [1-3]. Among patients with end-
stage renal disease, serum levels of FGF23 increase in
response to elevated serum phosphorus, and those of
α-Klotho decrease. Among patients with end-stage
renal disease, serum levels of FGF23 increase in response* Correspondence: ishizaka@poh.osaka-med.ac.jp
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unless otherwise stated.to elevated serum phosphorus. In addition, serum α-Klotho
decreases with the progression of renal dysfunction [4],
which may be attributed to the fact that the membrane
protein klotho is expressed predominantly in kidney and
brain and that renal expression of klotho is decreased in
patients with chronic kidney disease (CKD) [5,6]. FGF23
is presumed to exert extrarenal manifestations [7], includ-
ing left ventricular hypertrophy and cardiac systolic dys-
function [8,9]. Together with the observation that reduced
α-Klotho is associated with coronary artery disease [10],
these findings suggested that modulation of FGF23/α-
Klotho may represent one of the crucial factors underlying
the cardiac [11] and vascular remodeling observed in pa-
tients with CKD.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ated with left ventricular hypertrophy and cardiac systolic
dysfunction [12,13]. As a result, therapies that, directly or
indirectly, lower serum levels of FGF23 and, in reverse,
elevate the serum α-Klotho level, might represent a novel
target to slow the cardiac remodeling process [14]. Before
searching for effective therapeutic strategies, however, we
should analyze what determines FGF23/α-Klotho levels in
cardiology patients; only a little information is available
about FGF23/α-Klotho in non-CKD patients [15] as com-
pared with patients in cardiology patients undergoing
hemodialysis [16,17].
CKD is defined to be present when low glomerular fil-
tration rate (GFR) and/or enhanced urinary protein ex-
cretion, both of which conditions has been shown to be
associated with cardiac remodeling [18,19], exists for
certain period of time. However, relationship between
FGF23/α-Klotho and proteinuria seems to have been
less extensively examined thus far, as compared with
that between GFR and FGF23/α-Klotho [20]. To this
end, in the current study, we investigated the associ-
ation of the extent of proteinuria, as well as eGFR, with




The current retrospective study was approved by the
Ethics Committee of Osaka Medical College. Between
October 2012 and January 2014, 190 cardiac inpatients
were recruited who provided written informed consent
and for whom sufficient information regarding the data
analysis was available. After excluding five patients under-
going chronic hemodialysis, 185 patients were enrolled in
the current study.
Laboratory analysis
Aliquots of serum and plasma were obtained and stored
immediately at −80 degrees until use. Calcium (Ca), inor-
ganic phosphate, C-reactive protein (CRP), and B-type
natriuretic peptide (BNP) were measured by routine labora-
tory methods. When serum albumin was 4 mg/dL or lower,
serum Ca levels were corrected by the formula: Ca + (4–
[serum albumin]), and reported as corrected Ca (cCa).
Serum levels of intact FGF23 were measured using a
two-step FGF23 enzyme-linked immunosorbent assay
(ELISA) kit (Kainos Laboratories Inc., Tokyo, Japan),
and serum levels of soluble α-Klotho were measured
using a solid-phase sandwich ELISA kit (Immuno-
Biological Laboratories, Gunma, Japan) according to
the manufacturer’s instructions. The interclass correl-
ation coefficients (ICC) of intra- and inter-operator
reliability for α-Klotho were 0.97 and 0.94, respectively,
those for FGF23 have been described elsewhere [13].The eGFR was calculated by the following Modification
of Diet in Renal Disease equation for Japanese subjects:
eGFR= 194 × (serum creatinine)-1.094 × (age)-0.287 [21]. Urin-
ary albumin in spot urine was measured by turbidimetric
immunoassay and corrected to the urinary albumin level,
and expressed as mg of albumin per 1 g of creatinine
(urine albumin creatinine ratio, UACR).
Fractional excretion of calcium (FEca) was calculated
by the formula: FEca = ([urine calcium] × [serum creatinine])/
([serum calcium] × [urine creatinine]).Tubular fractional
reabsorption of phosphorus (TRP) was calculated by the
formula: TRP = 1-([urine phosphate] × [serum creatinine])/
([serum phosphate] × [urine creatinine]); and percent TRP
was calculated by multiplying TRP by 100. The tubular
maximum reabsorption of phosphorus per glomerular fil-
tration rate (TmP/GFR [mg/dL]) can be calculated by the
following equation [22]: If TRP is ≤ 0.86 (86%), then
TmP/GFR = TRP × (serum phosphate). If TRP is > 0.86
(86%), then TmP/GFR = (0.3 × TRP)/(1–0.8 × TRP)x(serum
phosphate) [23]. Urine phosphate/creatinine ratio, percent
TRP, and TmP/GFR were found to be normally distrib-
uted by Kolmogorov-Smirnov test. On the other hand,
eGFR, UACR, urine calcium creatinine ratio, and FEca
were not normally distributed, and they were log trans-
formed, termed log(eGFR), log(UACR), log(urine Ca/cr),
and log(FEca), respectively.Statistical analysis
Baseline characteristics were assessed with standard de-
scriptive statistics. Data were expressed as either mean ±
standard deviation or median and interquartile range.
For comparisons of differences between groups, analysis
of variance (ANOVA) was used for variables with nor-
mal distribution, and Kruskal-Wallis test was used when
data were not normally distributed. To assess the correl-
ation between two variables, a Pearson’s correlation test
was used to assess the correlation between two normally
distributed variables; for variables that were not normally
distributed, a Spearman rank correlation test was used.
For multivariate analysis, multivariate linear regression
and multivariate logistic regression analyses were used.
Data analysis was performed by SPSS statistics version
22.0 (IBM, Armonk, NY). A value of P < 0.05 was taken to
be statistically significant.Results
Patient characteristics
Among the 185 patients enrolled in the study, 135 were
male (73%). More than half of the study subjects were
taking ACE inhibitors and/or AT1 receptor blockers
(Table 1). Of the 185 patients, 44 (24%), 124 (67%), and
17 (9%) had an eGFR (mL/min/1.73 m2) of ≥60, between
30 and 60, and < 30, respectively. In addition, 135 (73%),
Table 1 Demographic characteristics of the study patients
Variables Variables
Clinical characteristics Laboratory measurements Median (Interquartile range)
Age 68.9 ± 11.3 Complete blood cell count
Sex (women/men) 50 / 135 White blood cell count. ×103/mL 5.9 (4.9 - 7.0)
Body mass index, kg/m2 23.3 ± 3.1 Hemoglobin, g/dL 13.5 (12.4 - 14.7)
Systolic blood pressure, mmHg 128.2 ± 19.5 Platelet count. ×104/mL 20.1 (17.2 - 25.3)
Cardiovascular disease Blood chemistry
Ischemic heart disease, n (%) 124 (67.0) Total protein, g/dL 6.9 (6.6 - 7.4)
Arrhythmia, n (%) 43 (23.2) Albumin, g/dL 4.0 (3.8 - 4.2)
Cardiomyopathy, n (%) 22 (11.9) Alanine aminotransferase, IU/L 19 (14–27)
NYHA class III/IV, n (%) 16 (8.6) Blood urea nitrogen, mg/dL 17 (14–21)
Aortic aneurysm, n (%) 10 (5.4) Serum creatinine, mg/dL 0.88 (0.74 - 1.08)
Peripheral artery disease, n (%) 19 (10.3) eGFR. mL/min/1.73 m2 49.5 ± 15.0
Valvular heart disease, n (%) 7 (3.8) C-reactive protein, mg/dL 0.10 (0.04 - 0.45)
Smoking status B-type natriuretic peptide, pg/mL 49.4 (22.3 - 123.4)
Never, n (%) 69 (37.3) Corrected calcium, mg/dL 9.1 (8.8 - 9.4)
Former, n (%) 89 (48.1) Inorganic phosphate, mg/dL 3.3 ± 0.5
Current, n (%) 27 (14.6) FGF23, pg/mL 46.9 (33.7 - 67.8)
α-Klotho, pg/mL 343 (218–474)
Medication
ACE inhibitors/ARB, n (%) 96 (51.9) Urine chemistry
Beta blockers, n (%) 72 (38.9) Albumin, g/dL 8.7 (4.5 - 34.0)
Calcium channel blockers, n (%) 84 (45.4) Creatinine, mg/dL 74.8 (42.9 - 126.4)
Aldosterone antagonist, n (%) 8 (4.3) Albumin/creatinine ratio, mg/g 12.9 (6.6 - 34.4)
Sulfonylurea, n (%) 16 (8.6) Calcium/creatinine ratio, mg/g 0.07 (0.04 - 0.12)
DPP4 inhibitors, n (%) 28 (15.1) Phosphate/creatinine ratio, mg/g 0.49 ± 0.21
Insulin, n (%) 15 (8.1) Fractional excretion of calcium, % 0.73 (0.42 - 1.12)
Loop, n (%) 32 (17.3) TRP, % 86.1 ± 6.7
Thiazide, n (%) 15 (8.1) TmP/GFR, mg/dL 2.9 (2.5 - 3.5)
Statin, n (%) 96 (51.9)
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of < 30 (normoalbuminic range), between 30 and 300
(microalbuminuric range), and ≥ 300 (macroalbuminuric
range), respectively. Serum FGF23 levels between pa-
tients who were and were not taking ACE inhibitor and/
or angiotensin II receptor blocker did not differ signifi-
cantly (data not shown). By contrast, α-Klotho levels in
patients who were taking ACE inhibitor and/or angio-
tensin II receptor blocker (median 317, interquartile
range 216–427 pg/mL, n = 96) were significantly lower
than those in patients who were not taking either drug
(median 397, interquartile range 221–520 pg/mL, n = 89)
(P = 0.045, by Mann–Whitney analysis).
When patients were categorized according to their
eGFR levels (Table 2), serum levels of FGF23 and α-
Klotho, and parameters related to urine excretion of cal-
cium or phosphate, except urine phosphate creatinineratio, were significantly different across the groups. For
example, α-Klotho, percent TRP and FEca showed a
graded decrease, and FGF23 showed a graded increase
with the progression of CKD stages. Serum concentra-
tions of FGF23 and α-Klotho in patients with grade 4,
but not those in patients with grade 3 CKD, differed sig-
nificantly from those in patients without CKD (Dunnett’s
post-hoc analysis).
Serum levels of FGF23 or α-Klotho, and the urine pa-
rameters described above, except TRP, did not differ
according to the albuminuric status (Table 3).
Correlation between serum FGF23/α-Klotho and eGFR/
UACR and other calcium phosphate metabolism-related
factors
Log(eGFR) was significantly associated with log(UACR)
with a correlation coefficient of −0.190 (P = 0.009). FGF23
Table 2 Laboratory data stratified by eGFR values
eGFR ≥60 mL/min/m2 eGFR 30–60 mL/min/m2 eGFR <30 mL/min/m2
Variables (n = 44) (n = 124) (n = 17) P value
eGFR, mL/min/1.73 m2 69.2 ± 8.7 45.9 ± 8.4 25.6 ± 8.4 <0.001
Urine albumin creatinine ratio 10 (7–55) 13 (6–27) 75 (10–196) 0.036
Serum cCa, mg/dL 9.1 (8.8 - 9.5) 9.1 (8.7 - 9.3) 9.1 (8.7 - 9.3) 0.508
Serum inorganic phosphate, mg/dL 3.40 (3.10 - 3.70) 3.30 (2.90 - 3.70) 3.30 (3.00 - 3.65) 0.546
Urine calcium creatinine ratio, mg/g 0.11 (0.07 - 0.17) 0.07 (0.04 - 0.11) 0.03 (0.01 - 0.05) <0.001
Fractional excretion of calcium, % 0.81 (0.48 - 1.30) 0.72 (0.42 - 1.05) 0.46 (0.17 - 0.89) 0.041
Urine phosphate creatinine ratio, mg/g 0.50 ± 0.23 0.49 ± 0.20 0.39 ± 0.15 0.149
TRP, % 90.1 ± 4.9 85.5 ± 6.2 80.2 ± 8.6 <0.001
TmP/GFR, mg/dL 3.3 (2.8 - 4.2) 2.8 (2.5 - 3.4) 2.6 (2.2 - 3.2) <0.001
FGF23, pg/mL 41.2 (29.4 - 62.3) 47.0 (35.3 - 67.9) 66.4 (45.6 - 111.3) 0.009
α-Klotho, mg/dL 425 (254–539) 351 (224–473) 211 (163–286) 0.001
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positively with log(UACR) (Figure 1). As we reported be-
fore, α-Klotho was not significantly correlated with serum
levels of either calcium or phosphate [12]; however,FGF23
showed a positive correlation with serum calcium, which
differed from our previous observation [12]. Among the
urine parameters, FGF23 was significantly correlated with
parameters related to calcium excretion, including log
(urine Ca/cr) or log(FEca), but not with parameters of
phosphate excretion, namely, urine phosphate creatinine
ratio, percent TRP, or TmP/GFR (Table 4). When patients
were divided according to their CKD status, a significant
association between FGF23 and calcium and between
FGF23 and phosphate was observed exclusively among
those with CKD (i.e., GFR < 60 mL/min/1.73 m2). Among
the group of patients with CKD, α-Klotho was signifi-
cantly correlated with parameters related to calcium ex-
cretion, but not with those related to phosphate excretion.Table 3 Laboratory data stratified by UACR values
UACR <30 mg/g cr U
Variables (n = 135)
eGFR, mL/min/1.73 m2 51 ± 14
Urine albumin creatinine ratio 9 (5–15) 7
Serum cCa, mg/dL 9.1 (8.8 - 9.4) 9
Serum inorganic phosphate, mg/dL 3.30 (2.90 - 3.70) 3
Urine calcium creatinine ratio 0.07 (0.04 - 0.12) 0
Fractional excretion of calcium, % 0.73 (0.43 - 1.06) 0
Urine phosphate creatinine ratio 0.47 ± 0.19
TRP, % 87.2 ± 5.7
TmP/GFR, mg/dL 3.0 (2.6 - 3.5) 2
FGF23, pg/mL 46.8 (34.3 - 67.0) 4
α-Klotho, mg/dL 345 (223–468) 3Linear regression analysis
Next, we performed univariate and multivariate analyses
for patients using log(FGF23) or log(α-Klotho) as an in-
dependent variable (Table 5). eGFR was associated with
both log(FGF23) and log(α-Klotho); and log(cCa) and in-
organic phosphate were associated significantly with log
(FGF23), but not with log(α-Klotho), consistent with the
correlation analysis. Multivariate stepwise regression
analysis showed that age, eGFR, log(cCa), and inorganic
phosphate were selected as significant predictor for log
(FGF23), and only eGFR was selected as a predictor for
log(α-Klotho).
We also performed a linear regression analysis after
dividing the study population according to their CKD sta-
tus. None of the parameters tested was selected as a sig-
nificant predictor for either log(FGF23) or log(α-Klotho)
among patients in the no CKD group (Table 6). By univar-
iate analysis, log(UACR) was found to be associated withACR 30–300 mg/g cr UACR ≥300 mg/g cr
(n = 40) (n = 10) P value
48 ± 17 39 ± 17 0.039
6 (51–154) 1241 (719–2045) <0.001
.3 (8.8 - 9.5) 9.3 (8.8 - 9.5) 0.530
.30 (2.90 - 3.50) 3.65 (3.30 - 3.98) 0.042
.07 (0.03 - 0.15) 0.07 (0.02 - 0.10) 0.789
.71 (0.36 - 1.50) 0.74 (0.38 - 1.33) 0.984
0.52 ± 0.23 0.59 ± 0.25 0.088
84.0 ± 8.0 80.6 ± 9.6 0.001
.7 (2.2 - 3.4) 2.9 (2.6 - 3.5) 0.186
4.1 (29.9 - 68.5) 58.3 (47.0 - 86.3) 0.330
30 (200–474) 358 (218–589) 0.736
A B C D
Figure 1 Scatter plots and correlation coefficients between FGF23 or α-Klotho, and estimated glomerular filtration rate (eGFR) or urine
albumin/creatinine ratio (UACR). A. Correlation between log(eGFR) and log(FGF23). B. Correlation between log(eGFR) and log(α-Klotho). C. Correlation
between log(UACR) and log(FGF23). D. Correlation between log(UACR) and log(α-Klotho). Spearman’s correlation analysis was performed.
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ciation did not remain significant in a stepwise multivari-
ate model.
Discussion
It was found that serum FGF23 was correlated with both
eGFR and UACR in a univariate model (Figure 1). When
the study patients were categorized by their eGFR values,
FGF23 showed a graded increase and α-Klotho showed a
graded decrease according to the progression of CKD
stages (Table 2). On the other hand, such an association
was not apparent when the patients were divided ac-
cording to the albuminuric status (Table 3). In the
multivariate regression model, eGFR was selected as, re-
spectively, a significant negative and positive predictor
for serum FGF23 and α-Klotho; in contrast, UACR was
not selected as a predictor (Table 5).
It is increasingly recognized that both a low glomeru-
lar filtration rate and increased urinary protein excretion
are associated with an adverse cardiac or cardiovascular
outcome [24,25]. Both low eGFR [11,18] and proteinuria
[26] have been shown to be associated with cardiac re-
modeling. On the other hand, as compared with theTable 4 Correlation between FGF23/α-Klotho and serum and
Total study population
Log (FGF23) Log (α-Klotho) L
Log (FGF23) - −0.14 0.064
Log (α-Klotho) −0.14 0.064 - −
Log (cCa) 0.22 0.003 0.06- 0.444 0
Inorganic phosphate 0.23 0.002 0.05 0.509 0
Log (urine Ca/cr) −0.15 0.039 0.22 0.003 −
Log (FEca) −0.15 0.045 0.15 0.037 −
Urine phosphate creatinine ratio 0.07 0.348 0.03 0.728 −
Percent TRP −0.14 0.064 0.11 0.124 0
Log (TmP/GFR) 0.07 0.355 0.04 0.634 0
For the correlation between log(FGF23) and log(α-Klotho) and between log(FGF23)
percent TRP, and log(TmP/GFR), Pearson’s correlation test was used. Spearman’s correlationship between eGFR and FGF23/α-Klotho, in-
formation seems to be limited regarding the relation-
ship association between proteinuria (or albuminuria)
and FGF23/α-Klotho. Lundberg et al. demonstrated that,
among patients with IgA nephropathy, FGF23 was sig-
nificantly correlated with both albuminuria and eGFR,
although they did not explore this relationship in a
multivariate model [27]. When we analyzed the patients
who did and did not have eGFR values in the CKD range
(i.e., < 60 mL/min/1.73 m2), FGF23 levels were found to
be related to eGFR in those with CKD, but not in those
without (Table 5). These findings were consistent with
the notion that factors other than eGFR, proteinuria, or
inorganic phosphate may have a role in modulating
FGF23 levels [15]. In our previous study, we showed
that, even among patients without CKD, higher serum
FGF23 tended to be associated with lower systolic func-
tion [12]; therefore, such factors, if present at all, should
be pursued among cardiology patients in future studies.
Klotho is expressed predominantly in the kidney and,
to the less extent, in the brain. As described above, previ-
ous studies have shown that, in parallel with the reduction
of glomerular filtration rate, renal expression of klotho isurine calcium/phosphate-related parameters
eGFR ≥60 mL/min/m2 eGFR <60 mL/min/m2
og (FGF23) Log (α-Klotho) Log (FGF23) Log (α-Klotho)
- −0.23 0.138 - −0.10 0.256
0.23 0.138 - −0.10 0.256 -
.13 0.395 0.09 0.553 0.26 0.002 0.05 0.559
.11 0.469 −0.25 0.104 0.27 0.001 −0.01 0.934
0.23 0.134 −0.05 0.735 −0.09 0.311 0.26 0.002
0.25 0.106 −0.04 0.786 −0.10 0.247 0.19 0.021
0.09 0.544 −0.13 0.411 0.12 0.153 0.08 0.363
.15 0.331 0.03 0.858 −0.14 0.099 0.08 0.331
.17 0.276 −0.13 0.385 0.10 0.247 0.04 0.638
or log(α-Klotho) and inorganic phosphate, urine phosphate creatinine ratio,
relation test was used otherwise.
Table 5 Linear regression analysis
Univariate model Stepwise multivariate model
Predictors Std β (95% confidence interval) P value Std β (95% confidence interval) P value
dependent variable: Log(FGF23)
Sex (male = 1) −0.02 (−0.17 - 0.12) 0.741
Age 0.21 (0.07 - 0.35) 0.004 0.16 (0.01 - 0.30) 0.034
eGFR −0.21 (−0.35 - -0.07) 0.004 −0.16 (−0.34 - -0.02) 0.027
Log(UACR) 0.13 (−0.01 - 0.28) 0.077
Log(cCa) 0.24 (0.10 - 0.38) 0.001 0.21 (0.07 - 0.35) 0.003
Inorganic phosphate 0.23 (0.09 - 0.37) 0.002 0.19 (0.05 - 0.33) 0.007
Dependent variable: log(α-Klotho)
Sex (male = 1) 0.00 (−0.14 - 0.15) 0.955
Age −0.14 (−0.28 - 0.01) 0.064
eGFR 0.24 (0.10 - 0.39) 0.001 0.24 (0.10 - 0.39) 0.001
Log(UACR) −0.01 (−0.15- 0.14) 0.931
Log(cCa) −0.03 (−0.18 - 0.12) 0.680
Inorganic phosphate −0.05 (−0.19 - 0.10) 0.509
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α-Klotho level among in patients with low eGFR [4].
These findings are consistent with the finding in the
current study, that serum α-Klotho was decreased espe-
cially in the patients in the higher CKD grades. On the
other hand, α-Klotho was not associated with the extent
of proteinuria, regardless of the presence or absence of a
decline in renal function in the current study.Table 6 Linear regression analysis among no-CKD and CKD g
eGFR ≥60 mL/min/m2
Univariate model







Sex (male = 1) 0.05 (−0.26 - 0.36) 0.743 −0.10
Age 0.08 (−0.23 - 0.39) 0.589 0.23
eGFR −0.02 (−0.34 - 0.29) 0.874 −0.19
Log(UACR) −0.05 (−0.36 - 0.26) 0.742 0.18
Log(cCa) 0.22 (−0.08 - 0.52) 0.150 0.24
Inorganic phosphate 0.11 (−0.20 - 0.42) 0.469 0.27
Dependent variable:
log(α-Klotho)
Sex (male = 1) 0.11 (−0.20 - 0.42) 0.474 0.02
Age −0.17 (−0.48 - 0.14) 0.269 −0.09
eGFR 0.09 (−0.22 - 0.40) 0.564 0.24
Log(UACR) −0.09 (−0.40 - 0.22) 0.551 0.02
Log(cCa) 0.00 (−0.31 - 0.31) 0.995 −0.03
Inorganic phosphate −0.19 (0.52 - 0.13) 0.237 −0.01Several experimental [28,29] and human studies [30]
suggested the possible relationship between the extent of
proteinuria and renal klotho expression. The observation
that drug intervention that can potently decrease pro-
teinuria increases renal Klotho expression or circulating
α-Klotho levels in aging-related renal injury [31] or dia-
betic nephropathy [32] may further suggest the possible
interaction between Klotho expression or secretion isroups
eGFR <60 mL/min/m2











(−0.27 - 0.06) 0.227
(0.07-0.39) 0.006 0.24 (0.08 - 0.39) 0.003
(−0.35 - -0.02) 0.025
(0.01 - 0.34) 0.037
(0.08 - 0.40) 0.004 0.21 (0.06 - 0.37) 0.008
(0.10 - 0.43) 0.001 0.21 (0.05 - 0.37) 0.011
(−0.14 - 0.19) 0.794
(−0.15 - 0.19) 0.794
(0.08 - 0.40) 0.004 0.24 (0.08 - 0.40) 0.004
(−0.15 - 0.18) 0.844
(−0.20 - 0.13) 0.685
(−0.17 - 0.16) 0.934
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reported that eGFR, but not proteinuria, was found to be
associated with α-Klotho level using a statistical model
that include both eGFR and proteinuria [4]. Karalliedde
et al. showed that, although angiotensin II receptor block-
age increased soluble Klotho, the extent of albuminuria
was not associated with soluble Klotho, in diabetic sub-
jects [33]. Similarly, Lim et al. reported that reduction of
proteinuria by angiotensin II receptor blocker, but not by
angiotensin converting enzyme (ACE) inhibitor resulted
in an increase in the circulating α-Klotho in diabetic pa-
tients. These finding may collectively suggest that extent
of proteinuria by itself is not be a determinant of circu-
lating α-Klotho, although how angiotensin II receptor
blocker cause an increase in α-klotho expression and
secretion is unknown [32]. Our data also indicate that
serum α-Klotho is related to renal function, but not to
the extent of proteinuria, at least among cardiology
patients.
We also examined the relationship between FGF23/
α-Klotho and urine excretion of calcium and phosphate
(Table 4). It was rather unexpected that FGF23 levels were
not significantly correlated with TmP/GFR. FGF23 regu-
lates urinary phosphate excretion, as well as production of
vitamin D and parathyroid hormone. FGF23 was shown
to be positively associated with TmP/GFR in healthy sub-
jects [34], and, in addition, phosphaturic activities of
FGF23 have also been convincingly demonstrated in the
genetically engineered animal models [35,36] and in a pa-
tient with high FGF23 levels due to tumor-induced osteo-
malacia [37].
On the other hand, Komo et al. reported in an analysis
of data from patients referred to their hospital for osteo-
porosis treatment, that serum FGF23 was not correlated
with inorganic phosphate, corrected calcium, or TmP/
GFR [38]. They speculated that association between
FGF23 and TmP/GFR may be weaker in the absence of
severe renal dysfunction. Consistent with their notion
findings, association between FGF23 and TmP/GFR was
significant, albeit borderline, among patients with CKD
in the current study population (Table 4). Of note, it is
known that resistance to the elevated FGF23 may occur
in some diseased conditions, such as autosomal domin-
ant polycystic kidney disease [39,40]. Although the pre-
cise mechanism of this resistance remains unclear,
decreased renal Klotho expression is presumed to play a
role. Whether FGF23 resistance is present among pa-
tients with certain cardiac or vascular disorder should
be investigated in future studies.
The current study has some limitations. First, ACE in-
hibitors and/or angiotensin II receptor blockers were pre-
scribed for a substantial proportion of the study subjects,
and patients who were taking these medications had lower
serum α-Klotho than those who were not. Because thiswas not a randomized interventional study, however, we
are not able to draw conclusions about whether or not
these medications increase or decrease serum α-Klotho.
Second, we excluded patients who were undergoing
chronic hemodialysis; therefore, the relationship between
FGF23/α-Klotho and renal function may be underesti-
mated [16].
Conclusions
Among cardiology patients, eGFR, but not the extent of
proteinuria, was independently associated with serum
levels of FGF23 and α-Klotho. In addition to clarifying the
prognostic importance of these molecules for the predic-
tion of outcome [41,42], the investigation of factors that
are and are not related to FGF23/α-Klotho should be con-
tinued in order to discover how to modulate the FGF23/
α-Klotho axis for the therapeutic purpose.
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